The new BINDAZYME™ C1q Binding CIC Elisa recently received FDA clearance as an aid in the diagnosis and monitoring of immune complex diseases, including systemic lupus erythematosis and rheumatoid arthritis. The semi-quantitative assay is designed to measure Circulating Immune Complexes (CIC) that bind C1q in human serum.
The assay features ready-to-use and color-coded reagents, calibrators and controls, break-apart wells, three 30-minute incubations, and common components that are interchangeable with other associated BINDAZYME assays, including ANA, ENA, and dsDNA. This assay is easily integrated into the laboratory workflow using automated or manual methods.
The Binding Site Inc
www.CLPmag.com
